Brokerages forecast that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will announce earnings per share of $0.08 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.11 and the lowest is $0.03. Amphastar Pharmaceuticals reported earnings per share of $0.12 in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings report on Thursday, November 14th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.34 per share for the current fiscal year, with EPS estimates ranging from $0.28 to $0.41. For the next fiscal year, analysts forecast that the company will report earnings of $0.92 per share, with EPS estimates ranging from $0.63 to $1.38. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 7th. The company reported $0.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.05. The business had revenue of $79.00 million for the quarter, compared to analyst estimates of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. Amphastar Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.03 EPS.

A number of research firms recently weighed in on AMPH. ValuEngine lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 20th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Wednesday, July 10th. TheStreet raised shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, August 7th. Finally, BidaskClub cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $24.64.

Amphastar Pharmaceuticals stock traded up $0.01 during midday trading on Wednesday, reaching $19.76. 904 shares of the stock were exchanged, compared to its average volume of 196,768. The company’s fifty day moving average is $21.24 and its 200-day moving average is $20.80. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.83 and a current ratio of 2.81. The firm has a market cap of $935.55 million, a PE ratio of 94.05 and a beta of 1.14. Amphastar Pharmaceuticals has a 52 week low of $17.71 and a 52 week high of $25.43.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,942 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $21.00, for a total transaction of $103,782.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Yakob Liawatidewi sold 1,515 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $21.24, for a total transaction of $32,178.60. Following the sale, the senior vice president now directly owns 36,670 shares of the company’s stock, valued at approximately $778,870.80. The disclosure for this sale can be found here. Insiders sold a total of 353,979 shares of company stock valued at $7,405,413 in the last ninety days. 30.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in AMPH. Rhumbline Advisers boosted its position in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Rhumbline Advisers now owns 106,120 shares of the company’s stock valued at $2,168,000 after buying an additional 2,177 shares during the period. Comerica Bank boosted its position in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Comerica Bank now owns 34,703 shares of the company’s stock valued at $730,000 after buying an additional 722 shares during the period. California Public Employees Retirement System boosted its position in Amphastar Pharmaceuticals by 179.7% during the 1st quarter. California Public Employees Retirement System now owns 71,540 shares of the company’s stock valued at $1,462,000 after buying an additional 45,966 shares during the period. New York State Common Retirement Fund boosted its position in Amphastar Pharmaceuticals by 6.2% during the 1st quarter. New York State Common Retirement Fund now owns 51,189 shares of the company’s stock valued at $1,046,000 after buying an additional 3,003 shares during the period. Finally, Great West Life Assurance Co. Can boosted its position in Amphastar Pharmaceuticals by 5.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 46,463 shares of the company’s stock valued at $949,000 after buying an additional 2,600 shares during the period. 47.27% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Elliott Wave Theory

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.